DIrect Oral Anticoagulation and Bioprothesis Aortic Valve

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1500 participants.

Also called NCT05687448

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05687448
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT05687448. Randomized; no masking; primary purpose treatment. Start 2025-09 (anticipated); primary completion 2025-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
Acronym
DIAMOND
Condition
Aortic Valve Disease
Intervention (Drug)
Apixaban 5 MG Oral Tablet
Intervention (Drug)
Aspirin 75 to 100mg once a day
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct05687448
Content hash
2b7e11fe6d0c4891ca1d8481f41a17e8503ecee481c12a7303eccfa5c50d63cf